The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer

Gynecologic Oncology

Volumn 108, Issue 2, 2008, Pages 287-292

  Zivanovic, Oliver ^a   Eisenhauer, Eric L ^a   Zhou, Qin ^a   Iasonos, Alexia ^a   Sabbatini, Paul ^a   Sonoda, Yukio ^a   Abu Rustum, Nadeem R ^a   Barakat, Richard R ^a   Chi, Dennis S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Ovarian cancer; Stage IIIC; Upper abdominal disease

Indexed keywords

ABDOMINAL DISEASE; ABDOMINAL SURGERY; ADULT; AGED; ANALYTIC METHOD; ARTICLE; ASCITES; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONTROLLED STUDY; DIAPHRAGM; FEMALE; HUMAN; LIVER; LIVER HILUS; MAJOR CLINICAL STUDY; OMENTUM; OUTCOME ASSESSMENT; OVARY CANCER; PANCREAS; PERITONEUM CANCER; PRIORITY JOURNAL; SPLEEN; STATISTICAL ANALYSIS; STOMACH; UTERINE TUBE CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OMENTUM; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 38649096926     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2007.10.001     Document Type: Article

References (27)

1. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
2. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
3. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., et al. Gynecologic Oncology Group. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354 (2006) 34-43
4. Alberts D.S., Liu P.Y., Hannigan E.V., O'Toole R., Williams S.D., Young J.A., et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335 (1996) 1950-1955
5. Markman M., Bundy B.N., Alberts D.S., Fowler J.M., Clark-Pearson D.L., Carson L.F., et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19 (2001) 1001-1007
6. Chi D.S., Venkatraman E.S., Masson V., and Hoskins W.J. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 77 (2000) 227-231
7. Memarzadeh S., Lee S.B., Berek J.S., and Farias-Eisner R. CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 13 (2003) 120-124
8. Saygili U., Guclu S., Uslu T., Erten O., Demir N., and Onvural A. Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?. Gynecol Oncol 86 (2002) 57-61
9. Axtell A.E., Lee M.H., Bristow R.E., Dowdy S.C., Cliby W.A., Raman S., et al. Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer. J Clin Oncol 25 (2007) 384-389
10. Fagotti A., Ferrandina G., Fanfani F., Ercoli A., Lorusso D., Rossi M., et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 13 (2006) 1156-1161
11. Fagotti A., Fanfani F., Ludovisi M., Lo Voi R., Bifulco G., Testa A.C., et al. Role of laparoscopy to assess the chance of optimal cytoreductive surgery in advanced ovarian cancer: a pilot study. Gynecol Oncol 96 (2005) 729-735
12. Kuhn W., Rutke S., Spathe K., Schmalfeldt B., Florack G., von Hundelshausen B., et al. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92 (2001) 2585-2591
13. Kuhn W., Florack G., Roder J., Schmalfeldt B., Pache L., Rust M., et al. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV. Int J Gynecol Cancer 8 1 (1998) 56-63
14. Chi D.S., Franklin C.C., Levine D.A., Akselrod F., Sabbatini P., Jarnagin W.R., et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 94 (2004) 650-654
15. Eisenhauer E.L., Abu-Rustum N.R., Sonoda Y., Levine D.A., Poynor E.A., Aghajanian C., et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol 103 (2006) 1083-1090
16. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
17. Curtin J.P., Malik R., Venkatraman E.S., Barakat R.R., and Hoskins W.J. Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 64 (1997) 9-12
18. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
19. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979 [discussion 979-80]
20. Eisenkop S.M., Spirtos N.M., Friedman R.L., Lin W.C., Pisani A.L., and Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol 90 (2003) 390-396
21. McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334 (1996) 1-6
22. Chi D.S., Eisenhauer E.L., Lang J., Huh J., Haddad L., Abu-Rustum N.R., et al. What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?. Gynecol Oncol 103 (2006) 559-564
23. Berek J.S., Hacker N.F., and Lagasse L.D. Rectosigmoid colectomy and reanastomosis to facilitate resection of primary and recurrent gynecologic cancer. Obstet Gynecol 64 (1984) 715-720
24. Clayton R.D., Obermair A., Hammond I.G., Leung Y.C., and McCartney A.J. The Western Australian experience of the use of en bloc resection of ovarian cancer with concomitant rectosigmoid colectomy. Gynecol Oncol 84 (2002) 53-57
25. Sonnendecker E.W., and Beale P.G. Rectosigmoid resection without colostomy during primary cytoreductive surgery for ovarian carcinoma. Int Surg 74 (1989) 10-12
26. Mourton S.M., Temple L.K., Abu-Rustum N.R., Gemignani M.L., Sonoda Y., Bochner B.H., et al. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99 (2005) 608-614
27. Sugarbaker P.H. Peritoneum as the first-line of defense in carcinomatosis. J Surg Oncol 95 (2007) 93-96